Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

License Agreements (Details)	1 Months Ended	3 Months Ended		6 Months Ended
License Agreements (Details)	Mar. 31, 2015 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Feb. 28, 2023 USD ($)	Jan. 31, 2019 USD ($)	May 31, 2016 USD ($) item
NeuPharma, Inc. \| Additional sales milestone
License Agreements
Maximum potential milestone payments	$ 40,000,000.0
NeuPharma, Inc. \| Clinical and development milestone
License Agreements
Maximum potential milestone payments	39,000,000.0
NeuPharma, Inc. \| Regulatory approvals to commercialize the products
License Agreements
Maximum potential milestone payments	22,500,000
Dana-Farber Cancer Institute
License Agreements
Maintenance fee	50,000
Dana-Farber Cancer Institute \| First commercial sale milestone
License Agreements
Maximum potential milestone payments	21,500,000
Dana-Farber Cancer Institute \| Additional sales milestone
License Agreements
Maximum potential milestone payments	$ 60,000,000.0
Revenue recognition milestone payments		$ 60,000,000.0		$ 60,000,000.0
Jubilant Biosys Limited \| Additional sales milestone
License Agreements
Maximum potential milestone payments								$ 89,300,000
Jubilant Biosys Limited \| Clinical and development milestone
License Agreements
Maximum potential milestone payments								88,400,000
Jubilant Biosys Limited \| Regulatory approvals to commercialize the products
License Agreements
Maximum potential milestone payments								$ 59,500,000
Adimab, LLC \| PD-L1 \| Research and development
License Agreements
Non-Refundable milestone payment						$ 2,200,000
Adimab, LLC \| Clinical and development milestone
License Agreements
Maximum potential milestone payments							$ 2,500,000
Collaboration Agreement With TGTX
License Agreements
Revenue recognition milestone revenue recognized		12,000,000	$ 16,000,000	41,000	$ 47,000
Collaboration Agreement With TGTX \| First commercial sale milestone \| PD-L1
License Agreements
Revenue recognition milestone payments		27,600,000		27,600,000
Collaboration Agreement With TGTX \| First commercial sale milestone \| PD-L1 GITR
License Agreements
Revenue recognition milestone payments		21,500,000		21,500,000
Collaboration Agreement With TGTX \| Clinical and development milestone \| PD-L1 GITR
License Agreements
Revenue recognition milestone payments		7,000,000.0		7,000,000.0
Collaboration Agreement With TGTX \| Commercial sales In specified territories \| PD-L1
License Agreements
Revenue recognition milestone payments		19,200,000		19,200,000
Collaboration Agreement With TGTX \| Commercial sales In specified territories \| PD-L1 GITR
License Agreements
Revenue recognition milestone payments		14,500,000		14,500,000
Collaboration Agreement With TGTX \| Clinical development and regulatory milestones \| PD-L1
License Agreements
Revenue recognition milestone payments		8,400,000		8,400,000
Sublicense Agreement with TGTX
License Agreements
Research and development cost								50.00%
Number of clinical development milestones \| item								3
Number of licensed products \| item								2
Sublicense Agreement with TGTX \| Additional sales milestone
License Agreements
Revenue recognition milestone payments								$ 89,300,000
Sublicense Agreement with TGTX \| Clinical and development milestone
License Agreements
Revenue recognition milestone payments								25,500,000
Sublicense Agreement with TGTX \| Five regulatory approvals and first commercial sales
License Agreements
Revenue recognition milestone payments								61,900,000
Sublicense Agreement with TGTX \| Clinical development and regulatory milestones
License Agreements
Revenue recognition milestone payments								$ 87,400,000
Collaboration Agreement With GITR
License Agreements
Revenue recognition milestone revenue recognized		$ 18,000,000	$ 2,000,000	$ 24,000	$ 23,000